Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.73 |
| ▸ | DRD4 | P21917 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9051915 | 0.94 | DRD2 (0.73) | DRD2DRD4MEN1ALDH1A1LMNA | |
| SCHEMBL3139402 | 0.91 | DRD2 (0.73) | DRD2DRD4MEN1KMT2AADRA1A | |
| SCHEMBL9052271 | 0.88 | DRD2 (0.78) | DRD2MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL8986029 | 0.85 | DRD2 (1.00) | DRD2DRD4MEN1KMT2AADRA1A | |
| SCHEMBL9053114 | 0.85 | DRD2 (0.73) | DRD2DRD4MEN1KMT2AADRA1A | |
| SCHEMBL9052262 | 0.81 | DRD2 (0.78) | DRD2DRD4ADRA1ADRD3 | |
| SCHEMBL3134734 | 0.81 | DRD2 (0.71) | DRD2DRD4MEN1KMT2AADRA1A | |
| SCHEMBL9053073 | 0.80 | DRD2 (0.80) | DRD2ADRA1ADRD3 | |
| SCHEMBL9050723 | 0.80 | DRD2 (0.83) | DRD2DRD4MEN1KMT2AADRA1A | |
| SCHEMBL9053428 | 0.80 | DRD2 (0.74) | DRD2ADRA1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101203492-B | Substituted butyrophenone derivatives | CLERA INC | 2011-05-04 | — | — | CN | disclosed |
| US-20100004289-A1 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | CLERA INC. (CA) | 2010-01-07 | — | — | US | disclosed |
| EP-1874730-A4 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | CLERA INC (CA) | 2009-06-10 | — | — | EP | disclosed |
| CN-101203492-A | Substituted butyrophenone derivatives | CLERA INC (CA) | 2008-06-18 | — | — | CN | disclosed |
| EP-1874730-A1 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | Clera Inc. (CA) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116848-A1 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | CLERA INC. (CA) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004289-A1 | SUBSTITUTED BUTYROPHENONE DERIVATIVES | DBH, SLC6A3, GABBR1 | DRD2 12/4885DRD4 5/4885MEN1 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.